CN107485399A - A kind of blood biochemical examines heparin tube - Google Patents
A kind of blood biochemical examines heparin tube Download PDFInfo
- Publication number
- CN107485399A CN107485399A CN201710824689.3A CN201710824689A CN107485399A CN 107485399 A CN107485399 A CN 107485399A CN 201710824689 A CN201710824689 A CN 201710824689A CN 107485399 A CN107485399 A CN 107485399A
- Authority
- CN
- China
- Prior art keywords
- blood
- heparin tube
- heparin
- silica
- examines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150343—Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
- A61B5/154—Devices using pre-evacuated means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A kind of blood biochemical examines heparin tube, is related to technical field of medical instruments.Blood biochemical examines the silica added with anti-coagulants and promotion platelet aggregation in heparin tube.Liquaemin/lithium can activate blood platelet, strengthen platelet aggregation, can also suppress the platelet aggregation of thrombin induction, so as to cause the blood platelet of existing aggregation in anticoagulant heparin blood, there is the single blood platelet being dispersed in part again.Silica can promote the aggregation of thrombin, and so as to reduce the blood platelet of single suspension in the heparin blood plasma after centrifugation, the big phenomenon of AST testing results error as caused by suspension blood platelet in Heparin plasma can be eliminated by adding silica.Using inert substance silica, both AST repeatability and correctness difference had been solved the problems, such as, do not influence the detection of other biochemical indicators again, there is higher practical significance and application value, the important breakthrough of heparin tube industry and emergency treatment biochemical investigation Pretreated technology can be considered as.
Description
Technical field
The present invention relates to technical field of medical instruments, is specifically related to a kind of blood biochemical and examines heparin tube.
Background technology
Blood biochemical inspection is an important content of medical test.Blood preparation pre-treating speed is improved, quick and precisely
Testing result is reported on ground, and valuable time is got to diagnose and giving emergency treatment to a patient, and is the target that vast medical laboratory work person pursues
And responsibility.
Blood parameters detect, and traditional method is in common test tube or test tube containing coagulant by blood collection
In；Fully solidified, after clot contraction after blood, serum could be centrifuged out and detected.This process usually requires 30 points
Clock or so.But the time spent by the patient of dysfunction of blood coagulation and anticoagulant therapy can be longer, thus cause to be delayed optimal rescue
Happened occasionally with the event of therapic opportunity.
In recent years, lot of domestic and international hospital, can be at once after collection using the heparin tube collection blood sample containing liquaemin/lithium
Isolate blood plasma and carry out biochemical investigation.This method without waiting for blood clotting, shrink, when significantly shortening Pretreated
Between.But found by long-term observation and substantial amounts of Comparability test, AST testing result poor repeatability in the blood plasma after separation,
Correctness is low, and compared with the serum that conventional method obtains, error is sometime up to decades of times, and is obtained through more product repetition tests
Confirm.Consulting literatures and consulting, which are gone together, also demonstrate that AST testing results error is a kind of generally existing greatly in liquaemin/lithium anti-freezing method
As.
For the big phenomenon of the error present in liquaemin/lithium anti-freezing method, its removing method has no that pertinent literature is reported.
The content of the invention
It is an object of the invention to provide a kind of blood biochemical to examine heparin tube, can eliminate liquaemin/lithium anti-freezing method institute
The big phenomenon of existing AST testing results error.
To achieve the above object, present invention employs following technical scheme：
A kind of blood biochemical examines heparin tube, and anti-coagulants is added with pipe, particularly, also added with promotion blood platelet in pipe
The silica of aggregation.
As optimal technical scheme, gathered according in pipe per mL blood-pressure meterses, the usage amount of silica is 10-80ug.
Further, anti-coagulants of the present invention has used heparinate, and heparinate may be selected to be liquaemin or heparin lithium.
As optimal technical scheme, gathered according in pipe per mL blood-pressure meterses, the usage amount of heparinate is 18-22IU.
By experimental studies have found that, liquaemin/lithium can activate blood platelet, strengthen platelet aggregation, can also suppress blood coagulation
The platelet aggregation of enzyme induction, so as to cause the blood platelet of existing aggregation in anticoagulant heparin blood, again there is part is single to be dispersed in
Blood platelet.The single blood platelet being dispersed in is not easy centrifugation, remained suspended in after centrifugation in blood plasma because density is low；And blood is small
Plate has AST active, therefore, detects accuracy (the Traditional Method application blood that the hematoblastic blood plasma containing part just have impact on AST results
Clearly, because blood platelet assembles completely, precipitates, therefore, the AST testing results of its serum are more accurate).
In order to solve this problem, inventor by substantial amounts of contrast test and it is related experimental studies have found that, titanium dioxide
Though silicon belongs to inert substance, the aggregation of thrombin can be promoted, so as to reduce single suspension in the heparin blood plasma after centrifugation
Blood platelet.Blood platelet has glutamic-oxalacetic transaminease (AST) active, adds silica in liquaemin/lithium anticoagulant tube, can eliminate liver
The big phenomenon of AST testing results error as caused by suspension blood platelet in plain anti-freezing blood plasma.
The blood biochemical of the present invention examines heparin tube, and its advantage is shown：
1) a kind of coagulant, is added in anticoagulant heparin agent --- silica, this is that one kind overcomes conventional art prejudice
Inventive concept, silica will not both destroy the anticoagulant effect of heparinate, and can help thoroughly to assemble blood platelet again, make
The blood platelet for being detected to AST and producing error is not contained in blood plasma after centrifugation.
2), silica can be first dissolved in absolute alcohol, heparin tube be dried drying, alcohol after loading heparin tube
It is evaporated, so that silica is fixed on blood sampling inside pipe wall.The addition of silica is summarized by many experiments
Out, cannot not only add it is excessive but also cannot add how much, otherwise will cause the appearance of detection error.
3), blood biochemical of the invention examines heparin tube, and its internal addO-on therapy can both only have heparinate and dioxy
Two kinds of components of SiClx, several additive components for not producing interference to biochemistry detection, the purpose master of addition can also be added in right amount
If heparinate and silica is set preferably to play its effect.
4), blood biochemical of the invention examines heparin tube, both can apply to normal pressure heparin tube, and can also be applied to vacuum
Heparin tube, the embodiment of its effect is not influenceed, but normal pressure heparin tube need to be sealed.
5), blood biochemical of the invention examines heparin tube to have higher practical significance and application value, can be considered as adopting
The important breakthrough of blood vessel industry and emergency treatment biochemical investigation Pretreated technology.The heparin tube application inert substance silica,
Both AST repeatability and correctness difference had been solved the problems, such as, and has not influenceed the detection of other biochemical indicators, and has shortened sample and locates in advance
The time of reason.
Embodiment
Below with reference to embodiment, the present invention is described in detail.But embodiment content is only to this hair
Bright done citing and explanation, affiliated those skilled in the art do various repair to described specific embodiment
Change or supplement or substituted using similar mode, design without departing from invention or surmount defined in the claims
Scope, protection scope of the present invention all should be belonged to.
Embodiment 1
A kind of blood biochemical examines heparin tube, and liquaemin and silica are added with pipe.Gathered according in pipe per mL blood
Meter, manage the liquaemin of the interior silica containing 18ug and 19IU.
The method of addition 18ug silica and 19IU liquaemin is in pipe：
1., first 6g nano silicon is dissolved in 1L absolute ethyl alcohol, add 50ul silicone oil (dispersant, prevent
Only precipitation of silica), it is well mixed.
2., take 3ul mixture load heparin tube, then to heparin tube carry out 80 DEG C dry drying, evaporated alcohol
Fall, so that nano silicon is fixed on blood sampling inside pipe wall.
3., by existing method by liquaemin be added to heparin tube in.
Embodiment 2
A kind of blood biochemical examines heparin tube, and liquaemin and silica are added with pipe.Gathered according in pipe per mL blood
Meter, manage the liquaemin of the interior silica containing 80ug and 22IU.
The method of addition 80ug silica and 22IU liquaemin is in pipe：
1., first 10g nano silicon is dissolved in 1L absolute ethyl alcohol, add 50ul silicone oil (dispersant, prevent
Only precipitation of silica), it is well mixed.
2., take 8ul mixture load heparin tube, then to heparin tube carry out 80 DEG C dry drying, evaporated alcohol
Fall, so that nano silicon is fixed on blood sampling inside pipe wall.
3., by existing method by liquaemin be added to heparin tube in.
Embodiment 3
A kind of blood biochemical examines heparin tube, and liquaemin and silica are added with pipe.Gathered according in pipe per mL blood
Meter, manage the liquaemin of the interior silica containing 48ug and 18IU.
The method of addition 48ug silica and 18IU liquaemin is in pipe：
1., first 6g nano silicon is dissolved in 1L absolute ethyl alcohol, add 50ul silicone oil (dispersant, prevent
Only precipitation of silica), it is well mixed.
2., take 8ul mixture load heparin tube, then to heparin tube carry out 80 DEG C dry drying, evaporated alcohol
Fall, so that nano silicon is fixed on blood sampling inside pipe wall.
3., by existing method by liquaemin be added to heparin tube in.
Embodiment 4
A kind of blood biochemical examines heparin tube, and heparin lithium and silica are added with pipe.Gathered according in pipe per mL blood
Meter, manage the heparin lithium of the interior silica containing 30ug and 20IU.
The method of addition 30ug silica and 20IU heparin lithium is in pipe：
1., first 10g nano silicon is dissolved in 1L absolute ethyl alcohol, add 50ul silicone oil (dispersant, prevent
Only precipitation of silica), it is well mixed.
2., take 3ul mixture load heparin tube, then to heparin tube carry out 80 DEG C dry drying, evaporated alcohol
Fall, so that nano silicon is fixed on blood sampling inside pipe wall.
3., by existing method by heparin lithium be added to heparin tube in.
Embodiment 5
A kind of blood biochemical examines heparin tube, and heparin lithium and silica are added with pipe.Gathered according in pipe per mL blood
Meter, manage the heparin lithium of the interior silica containing 49ug and 21IU.
The method of addition 49ug silica and 21IU heparin lithium is in pipe：
1., first 7g nano silicon is dissolved in 1L absolute ethyl alcohol, add 50ul silicone oil (dispersant, prevent
Only precipitation of silica), it is well mixed.
2., take 7ul mixture load heparin tube, then to heparin tube carry out 80 DEG C dry drying, evaporated alcohol
Fall, so that nano silicon is fixed on blood sampling inside pipe wall.
3., by existing method by heparin lithium be added to heparin tube in.
Embodiment 6
A kind of blood biochemical examines heparin tube, and heparin lithium and silica are added with pipe.Gathered according in pipe per mL blood
Meter, manage the heparin lithium of the interior silica containing 45ug and 18IU.
The method of addition 45ug silica and 18IU heparin lithium is in pipe：
1., first 9g nano silicon is dissolved in 1L absolute ethyl alcohol, add 50ul silicone oil (dispersant, prevent
Only precipitation of silica), it is well mixed.
2., take 5ul mixture load heparin tube, then to heparin tube carry out 80 DEG C dry drying, evaporated alcohol
Fall, so that nano silicon is fixed on blood sampling inside pipe wall.
3., by existing method by heparin lithium be added to heparin tube in.
Contrast test
5 groups of samples are taken to carry out detecting AST indexs, every group of sample is handled according to 3 kinds of approach respectively, 1. quiet using tradition
Put, centrifugal method acquisition sample A (serum), 2., using commercially available blackish green liquaemin heparin tube gather blood sample, then directly
Centrifugation obtains sample B (blood plasma), 3., using the heparin tube of the present invention gathers blood sample, then directly centrifugation obtains sample C
(blood plasma).As a result it is as shown in the table.
By upper table data, it can analyze and draw：
1., centrifugation after detect and centrifuge immediately after detect again within 10,20 minutes, to traditionally standing, centrifugal method obtains
Serum for, the amplitude of variation of its AST detected value is smaller, and maximum deviation is 2.236% (sample 2), testing result compared with
To be accurate, and repeatability is preferably.
2., detect and centrifuge immediately after centrifugation after detect again within 10,20 minutes, to being taken a blood sample using commercially available blackish green liquaemin
For the blood plasma that pipe collection blood, centrifugation obtain, the amplitude of variation of its AST detected value is very big, and maximum deviation reaches
58.583% (sample 5), minimum deflection have also reached 8.122% (sample 1), and testing result repeatability is poor.
3., centrifugation after detect and centrifuge immediately after detect again within 10,20 minutes, to using the present invention heparin tube gather blood
For the blood plasma that liquid, centrifugation obtain, the amplitude of variation of its AST detected value is smaller, and maximum deviation is only 1.478% (sample 3),
Deviation ratio is also low compared with to conventional method, and testing result is more accurate, and repeatability is preferably.
4., in the conventional way obtain Virus monitory on the basis of, either centrifuge after detect immediately, or centrifugation after 10,20
Minute is detected again, and the AST testing results of the blood plasma obtained using the heparin tube collection blood of the present invention, centrifugation are more accurate, phase
Also only have 2.236% (sample 2) to deviation ratio maximum.And blood is gathered using commercially available blackish green liquaemin heparin tube, centrifuges and obtains
The AST testing results correctness of the blood plasma obtained is but very low, and relative deviation rate has been up to 103.448% (sample 3), detection
As a result has no reference significance.
In summary：The blood biochemical of the present invention examines heparin tube, perfect can solve asking for AST repeatability and correctness difference
Topic, and shorten the time of Pretreated.
Claims (5)
1. a kind of blood biochemical examines heparin tube, anti-coagulants is added with pipe, it is characterised in that：It is also small added with promotion blood in pipe
The silica of plate aggregation.
2. blood biochemical as claimed in claim 1 examines heparin tube, it is characterised in that：According to collection in pipe per mL blood-pressure meterses, two
The usage amount of silica is 10-80ug.
3. blood biochemical as claimed in claim 1 examines heparin tube, it is characterised in that：The anti-coagulants is heparinate.
4. blood biochemical as claimed in claim 3 examines heparin tube, it is characterised in that：Gathered according in pipe per mL blood-pressure meterses, liver
The usage amount of plain salt is 18-22IU.
5. the blood biochemical as described in claim 3 or 4 examines heparin tube, it is characterised in that：The heparinate be liquaemin or
Heparin lithium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710824689.3A CN107485399A (en) | 2017-09-14 | 2017-09-14 | A kind of blood biochemical examines heparin tube |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710824689.3A CN107485399A (en) | 2017-09-14 | 2017-09-14 | A kind of blood biochemical examines heparin tube |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107485399A true CN107485399A (en) | 2017-12-19 |
Family
ID=60652584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710824689.3A Pending CN107485399A (en) | 2017-09-14 | 2017-09-14 | A kind of blood biochemical examines heparin tube |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107485399A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109280097A (en) * | 2018-05-18 | 2019-01-29 | 山阳县恒桓生物科技有限公司 | A kind of anti-coagulant heparin production of chemicals technique |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2152508Y (en) * | 1993-06-19 | 1994-01-12 | 韩建礼 | Automatic hemospast |
| CN1096373A (en) * | 1993-06-09 | 1994-12-14 | 中国科学院大连化学物理研究所 | The preparation method of a kind of serum separation gel and heparin tube |
| JP2005006821A (en) * | 2003-06-18 | 2005-01-13 | Olympus Corp | Blood sampling equipment and method for separating blood into plasma layer / hemocyte layer |
| CN102007049A (en) * | 2008-03-20 | 2011-04-06 | Inmat公司 | Collection container assembly with nanocomposite barrier coating |
| CN202086790U (en) * | 2011-05-24 | 2011-12-28 | 河北鑫乐科技有限公司 | Anticoagulation blood collection tube |
| CN102764133A (en) * | 2012-08-10 | 2012-11-07 | 上海科华检验医学产品有限公司 | Vacuum blood collection tube and method thereof capable of directly separating blood plasma |
| CN103837380A (en) * | 2012-11-22 | 2014-06-04 | 白杰 | Blending-free rapid blood coagulant |
| CN204542153U (en) * | 2015-04-19 | 2015-08-12 | 黄燎源 | A kind of medical blood taking pipe |
| CN105559799A (en) * | 2015-12-18 | 2016-05-11 | 长沙汇一制药机械有限公司 | Vacuum blood collection tube |
-
2017
- 2017-09-14 CN CN201710824689.3A patent/CN107485399A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1096373A (en) * | 1993-06-09 | 1994-12-14 | 中国科学院大连化学物理研究所 | The preparation method of a kind of serum separation gel and heparin tube |
| CN2152508Y (en) * | 1993-06-19 | 1994-01-12 | 韩建礼 | Automatic hemospast |
| JP2005006821A (en) * | 2003-06-18 | 2005-01-13 | Olympus Corp | Blood sampling equipment and method for separating blood into plasma layer / hemocyte layer |
| CN102007049A (en) * | 2008-03-20 | 2011-04-06 | Inmat公司 | Collection container assembly with nanocomposite barrier coating |
| CN202086790U (en) * | 2011-05-24 | 2011-12-28 | 河北鑫乐科技有限公司 | Anticoagulation blood collection tube |
| CN102764133A (en) * | 2012-08-10 | 2012-11-07 | 上海科华检验医学产品有限公司 | Vacuum blood collection tube and method thereof capable of directly separating blood plasma |
| CN103837380A (en) * | 2012-11-22 | 2014-06-04 | 白杰 | Blending-free rapid blood coagulant |
| CN204542153U (en) * | 2015-04-19 | 2015-08-12 | 黄燎源 | A kind of medical blood taking pipe |
| CN105559799A (en) * | 2015-12-18 | 2016-05-11 | 长沙汇一制药机械有限公司 | Vacuum blood collection tube |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109280097A (en) * | 2018-05-18 | 2019-01-29 | 山阳县恒桓生物科技有限公司 | A kind of anti-coagulant heparin production of chemicals technique |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5091304A (en) | Whole blood activated partial thromboplastin time test and associated apparatus | |
| CN106170697B (en) | Blood status analytical equipment, blood status analysis system, blood status analysis method and storage device | |
| BR112015030965B1 (en) | method for separating sporadic cells from bodily fluids, and apparatus for performing the aforementioned method | |
| Lippi | Interference studies: focus on blood cell lysates preparation and testing | |
| CN107485399A (en) | A kind of blood biochemical examines heparin tube | |
| Babic et al. | Effect of blood collection tubes on the incidence of artifactual hyperkalemia on patient samples from an outreach clinic | |
| Hayakawa et al. | Rapid evaluation of fibrinogen levels using the CG02N whole blood coagulation analyzer | |
| Gubbe et al. | Validation of virus NAT for HIV, HCV, HBV and HAV using post-mortal blood samples | |
| CN110346443A (en) | The method for detecting A2 beta-casein content in cow's milk | |
| CN101880706A (en) | Direct fungus detection tachypleus amebocyte lysate box and method | |
| CN104698159B (en) | A kind of detection method of endotoxin content | |
| CN110031555A (en) | A kind of method of separation detection serum lipoprotein | |
| CN110187131A (en) | A method of correcting haemolysis influences red blood cell series parameter detecting | |
| Zimmermann et al. | In vitro stability of heat shock protein 27 in serum and plasma under different pre-analytical conditions: implications for large-scale clinical studies | |
| CN213643745U (en) | Ultrafiltration tube for nucleic acid research and detection | |
| CN102564917A (en) | Novel method for detecting platelet aggregation ability | |
| Kanias et al. | Determination of lipid peroxidation in desiccated red blood cells | |
| Travagli et al. | Comparison of blood viscosity using a torsional oscillation viscometer and a rheometer | |
| CN113721033A (en) | U-shaped microporous plate, kit and application thereof | |
| CN108181470B (en) | Kit and method for detecting contents of endotoxin and (1-3) - β -D-glucan in jaundice blood sample | |
| Wang et al. | Changes of Plasma Blood Ammonia Levels of Chinese Healthy People and the Establishment of Reference Intervals. | |
| Hsaio et al. | Influence of Hemolysis on the Measurement of Serum Cortisol Levels by Radioimmunoassay Methods | |
| JP2005006821A (en) | Blood sampling equipment and method for separating blood into plasma layer / hemocyte layer | |
| JP5963984B2 (en) | Sample pretreatment method for thyroid stimulating antibody measurement | |
| CN110346458A (en) | Biomarker and application thereof in the blood of immunological rejection occurs for early detection Post kidney transplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171219 |